Grace Therapeutics
GRCE
28 hedge funds and large institutions have $1.44M invested in Grace Therapeutics in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 5 closing their positions.
3,299% more capital inflows, than outflows
Capital inflows: $731K | Capital outflows: $21.5K
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
22% more funds holding
Funds holding: 23 → 28 (+5)
2.92% more ownership
Funds ownership: 1.36% → 4.28% (+2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$463K |
| 2 |
Virtu Financial
New York
|
+$133K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$65.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$27.3K |
| 5 |
HRT Financial
New York
|
+$10.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$12K |
| 2 |
Avantax Advisory Services
Dallas,
Texas
|
-$3K |
| 3 |
Sargent Investment Group
Bethesda,
Maryland
|
-$3K |
| 4 |
Two Sigma Securities
New York
|
-$3K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$485 |
GRCE Hedge Fund Activity: Q4 2020 in Review
28 of the 5,679 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q4 2020, worth a combined $1.44M — up 458% from $258K a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new GRCE positions and 5 closed out — a net gain of 5 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $463K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $12K sold.
- 28 institutional investors held Grace Therapeutics (GRCE) as of Q4 2020, up from 23 in Q3 2020.
- Funds reported $1.44M of Grace Therapeutics stock for Q4 2020, up 458% quarter-over-quarter.
- 10 funds opened new Grace Therapeutics positions in Q4 2020 and 5 closed out, a net change of +5 holders.
- The largest Grace Therapeutics buyer in Q4 2020 was Renaissance Technologies, an estimated $463K added.
- The largest Grace Therapeutics seller in Q4 2020 was Susquehanna International Group, an estimated $12K sold.
Based on aggregated 13F filings for Q4 2020.